[Progress in diagnosis and treatment of lung cancer].
Fukuoka
Masahiro
M
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis* / Q000628:therapy*; D018288:Carcinoma, Small Cell / Q000175:diagnosis* / Q000628:therapy*; D002945:Cisplatin / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D016228:Endothelial Growth Factors / Q000276:immunology; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D000077156:Gefitinib; D015316:Genetic Therapy; D006801:Humans; D006877:Hydroxamic Acids / Q000627:therapeutic use; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000628:therapy*; D008222:Lymphokines / Q000276:immunology; D008403:Mass Screening; D008666:Metalloendopeptidases / Q000037:antagonists & inhibitors; D011799:Quinazolines / Q000627:therapeutic use; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D000911:Antibodies, Monoclonal; D016228:Endothelial Growth Factors; D004791:Enzyme Inhibitors; D006877:Hydroxamic Acids; D008222:Lymphokines; D011799:Quinazolines; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; C100342:marimastat; D020794:Receptor Protein-Tyrosine Kinases; D008666:Metalloendopeptidases; D002945:Cisplatin; D000077156:Gefitinib